BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tunuguntla HS, Jorda M. Diagnostic and prognostic molecular markers in renal cell carcinoma. J Urol 2008;179:2096-102. [PMID: 18423738 DOI: 10.1016/j.juro.2008.01.083] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Sakai I, Miyake H, Muramaki M, Kondo Y, Kusuda Y, Yamada Y, Fujisawa M. Significant impact of age at diagnosis on the prognosis of Japanese patients with pT1 renal cell carcinoma following surgical resection: PROGNOSIS OF PATIENTS WITH pT1 RENAL CELL CARCINOMA. BJU International 2012;109:695-9. [DOI: 10.1111/j.1464-410x.2011.10451.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Sakai I, Miyake H, Takenaka A, Fujisawa M. Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU International 2009;104:942-6. [DOI: 10.1111/j.1464-410x.2009.08591.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
3 Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE, Blute ML, Kwon ED. Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer 2009;115:2092-103. [PMID: 19296514 DOI: 10.1002/cncr.24263] [Cited by in Crossref: 88] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
4 Campbell SC, Lane BR. Malignant Renal Tumors. Campbell-Walsh Urology. Elsevier; 2012. pp. 1413-1474.e33. [DOI: 10.1016/b978-1-4160-6911-9.00049-9] [Cited by in Crossref: 22] [Article Influence: 2.2] [Reference Citation Analysis]
5 Na N, Li H, Xu C, Miao B, Hong L, Huang Z, Jiang Q. High expression of Aldolase A predicts poor survival in patients with clear-cell renal cell carcinoma. Ther Clin Risk Manag 2017;13:279-85. [PMID: 28280347 DOI: 10.2147/TCRM.S123199] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
6 Wang R, Li AY, Wood DP Jr. The role of percutaneous renal biopsy in the management of small renal masses. Curr Urol Rep 2011;12:18-23. [PMID: 20949338 DOI: 10.1007/s11934-010-0149-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
7 Lucarelli G, Galleggiante V, Rutigliano M, Sanguedolce F, Cagiano S, Bufo P, Lastilla G, Maiorano E, Ribatti D, Giglio A, Serino G, Vavallo A, Bettocchi C, Selvaggi FP, Battaglia M, Ditonno P. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma. Oncotarget 2015;6:13371-86. [PMID: 25945836 DOI: 10.18632/oncotarget.3823] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 12.3] [Reference Citation Analysis]
8 Johann DJ Jr, Wei BR, Prieto DA, Chan KC, Ye X, Valera VA, Simpson RM, Rudnick PA, Xiao Z, Issaq HJ, Linehan WM, Stein SE, Veenstra TD, Blonder J. Combined blood/tissue analysis for cancer biomarker discovery: application to renal cell carcinoma. Anal Chem 2010;82:1584-8. [PMID: 20121140 DOI: 10.1021/ac902204k] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
9 Harada K, Miyake H, Kusuda Y, Fujisawa M. Expression of epithelial-mesenchymal transition markers in renal cell carcinoma: impact on prognostic outcomes in patients undergoing radical nephrectomy: EPITHELIAL-MESENCHYMAL TRANSITION MARKERS IN RCC. BJU International 2012;110:E1131-7. [DOI: 10.1111/j.1464-410x.2012.11297.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
10 Mader P, Brynda J, Gitto R, Agnello S, Pachl P, Supuran CT, Chimirri A, Řezáčová P. Structural Basis for the Interaction Between Carbonic Anhydrase and 1,2,3,4-tetrahydroisoquinolin-2-ylsulfonamides. J Med Chem 2011;54:2522-6. [DOI: 10.1021/jm2000213] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
11 Calvo E, Maroto P, del Muro XG, Climent MÁ, González-larriba JL, Esteban E, López R, Paz-ares L, Bellmunt J, Castellano D. Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. Cancer Metastasis Rev 2010;29:1-10. [DOI: 10.1007/s10555-010-9231-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
12 Mehta S, Shelling A, Muthukaruppan A, Lasham A, Blenkiron C, Laking G, Print C. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol. 2010;2:125-148. [PMID: 21789130 DOI: 10.1177/1758834009360519] [Cited by in Crossref: 114] [Cited by in F6Publishing: 102] [Article Influence: 10.4] [Reference Citation Analysis]
13 Lucarelli G, Ditonno P, Bettocchi C, Vavallo A, Rutigliano M, Galleggiante V, Larocca AM, Castellano G, Gesualdo L, Grandaliano G, Selvaggi FP, Battaglia M. Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. Dis Markers 2014;2014:689795. [PMID: 24692843 DOI: 10.1155/2014/689795] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
14 Iafolla MAJ, Picardo S, Aung K, Hansen AR. Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. JNCI Cancer Spectr 2020;4:pkaa050. [PMID: 33134830 DOI: 10.1093/jncics/pkaa050] [Reference Citation Analysis]
15 Greef B, Eisen T. Medical treatment of renal cancer: new horizons. Br J Cancer 2016;115:505-16. [PMID: 27490806 DOI: 10.1038/bjc.2016.230] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 7.5] [Reference Citation Analysis]
16 West JM, Ma D, Mott SL, Brown JA. Cell cycle progression score has potential prognostic value for stage T1 renal cell carcinomas. Urol Oncol 2020;38:545-52. [PMID: 32081562 DOI: 10.1016/j.urolonc.2019.12.025] [Reference Citation Analysis]
17 Laird A, O'Mahony FC, Nanda J, Riddick AC, O'Donnell M, Harrison DJ, Stewart GD. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One 2013;8:e60483. [PMID: 23577117 DOI: 10.1371/journal.pone.0060483] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
18 Chen Y, Mu C, Huang J. Clinical Significance of Programmed Death-1 Ligand-1 Expression in Patients with Non-Small Cell Lung Cancer: A 5-year-follow-up Study. Tumori 2012;98:751-5. [DOI: 10.1177/030089161209800612] [Cited by in Crossref: 131] [Cited by in F6Publishing: 61] [Article Influence: 32.8] [Reference Citation Analysis]
19 Xu G, Xiang CQ, Lu Y, Kang XN, Liao P, Ding Q, Zhang YF. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma. Cancer Lett 2009;282:205-13. [PMID: 19362769 DOI: 10.1016/j.canlet.2009.03.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
20 Lucarelli G, Galleggiante V, Rutigliano M, Vavallo A, Ditonno P, Battaglia M. Isolation and Characterization of Cancer Stem Cells in Renal Cell Carcinoma. Urologia 2015;82:46-53. [DOI: 10.5301/uro.5000099] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
21 Tu X, Zhuang J, Wang W, Zhao L, Zhao L, Zhao J, Deng C, Qiu S, Zhang Y. Screening and identification of a renal carcinoma specific peptide from a phage display peptide library. J Exp Clin Cancer Res 2011;30:105. [PMID: 22071019 DOI: 10.1186/1756-9966-30-105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
22 Huang Y, Murakami T, Sano F, Kondo K, Nakaigawa N, Kishida T, Kubota Y, Nagashima Y, Yao M. Expression of Aquaporin 1 in Primary Renal Tumors: A Prognostic Indicator for Clear-Cell Renal Cell Carcinoma. European Urology 2009;56:690-9. [DOI: 10.1016/j.eururo.2008.10.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
23 Yu Q, Liu Y, Zheng X, Zhu Q, Shen Z, Wang H, He H, Lin N, Jiang H, Yu L, Zeng S. Histone H3 Lysine 4 Trimethylation, Lysine 27 Trimethylation, and Lysine 27 Acetylation Contribute to the Transcriptional Repression of Solute Carrier Family 47 Member 2 in Renal Cell Carcinoma. Drug Metab Dispos 2016;45:109-17. [DOI: 10.1124/dmd.116.073734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zaldumbide L, Erramuzpe A, Guarch R, Cortés JM, López JI. Large (>3.8 cm) clear cell renal cell carcinomas are morphologically and immunohistochemically heterogeneous. Virchows Arch 2015;466:61-6. [DOI: 10.1007/s00428-014-1673-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhuang J, Tu X, Cao K, Guo S, Mao X, Pan J, Huang B, Chen X, Gao Y, Qiu S. The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma. J Exp Clin Cancer Res 2014;33:25. [PMID: 24606948 DOI: 10.1186/1756-9966-33-25] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
26 Zerati M, Leite KR, Pontes-Junior J, Segre CC, Reis ST, Srougi M, Dall'Oglio MF. Carbonic Anhydrase IX is not a predictor of outcomes in non-metastatic clear cell renal cell carcinoma - a digital analysis of tissue microarray. Int Braz J Urol 2013;39:484-92. [PMID: 24054396 DOI: 10.1590/S1677-5538.IBJU.2013.04.05] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
27 Minamida S, Iwamura M, Kodera Y, Kawashima Y, Tabata K, Matsumoto K, Fujita T, Satoh T, Maeda T, Baba S. 14-3-3 protein beta/alpha as a urinary biomarker for renal cell carcinoma: proteomic analysis of cyst fluid. Anal Bioanal Chem 2011;401:245-52. [PMID: 21553213 DOI: 10.1007/s00216-011-5057-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
28 Nishikawa M, Miyake H, Harada K, Fujisawa M. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy. Urol Oncol 2014;32:49.e15-21. [PMID: 24239474 DOI: 10.1016/j.urolonc.2013.07.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
29 Montani M, Heinimann K, von Teichman A, Rudolph T, Perren A, Moch H. VHL-gene deletion in single renal tubular epithelial cells and renal tubular cysts: further evidence for a cyst-dependent progression pathway of clear cell renal carcinoma in von Hippel-Lindau disease. Am J Surg Pathol 2010;34:806-15. [PMID: 20431476 DOI: 10.1097/PAS.0b013e3181ddf54d] [Cited by in Crossref: 52] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
30 Vavallo A, Simone S, Lucarelli G, Rutigliano M, Galleggiante V, Grandaliano G, Gesualdo L, Campagna M, Cariello M, Ranieri E, Pertosa G, Lastilla G, Selvaggi FP, Ditonno P, Battaglia M. Pre-existing type 2 diabetes mellitus is an independent risk factor for mortality and progression in patients with renal cell carcinoma. Medicine (Baltimore) 2014;93:e183. [PMID: 25501064 DOI: 10.1097/MD.0000000000000183] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
31 Muramaki M, Miyake H, Sakai I, Kondo Y, Kusuda Y, Yamada Y, Fujisawa M. Age at diagnosis as a powerful predictor for disease recurrence after radical nephrectomy in Japanese patients with pT1 renal cell carcinoma: Prognosis in pT1 renal cell carcinoma. International Journal of Urology 2011;18:121-5. [DOI: 10.1111/j.1442-2042.2010.02683.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
32 Porta C, Figlin RA. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors. J Urol 2009;182:2569-77. [PMID: 19836781 DOI: 10.1016/j.juro.2009.08.085] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 4.5] [Reference Citation Analysis]